Fentanyl News and Research

RSS

Fentanyl is a powerful synthetic opiate analgesic similar to but more potent than morphine. It is typically used to treat patients with severe pain, or to manage pain after surgery. It is also sometimes used to treat people with chronic pain who are physically tolerant to opiates. It is a schedule II prescription drug.

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

BioDelivery Sciences International, Inc. has received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis.

6 Oct 2009

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei R&D Ltd., its wholly owned UK subsidiary, has entered into an agreement to assign its rights to the assets of AD 923, an optimised, sublingual formulation of the opioid analgesic fentanyl for the treatment of cancer breakthrough pain, as well as to the device for drug administration to Pharmasol R&D Ltd., a privately held UK company.

6 Oct 2009

FDA accepts ProStrakan's Abstral NDA filing for review

Orexo AB (STO:ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK), has announced that the New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA).

6 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

BioDelivery Sciences International files NDS for BEMA Fentanyl

BioDelivery Sciences International, Inc.today announced the filing of a New Drug Submission (NDS) to Health Canada, the regulatory authority in Canada, for BEMA Fentanyl, also known as fentanyl buccal soluble film. BEMA Fentanyl is marketed in the U.S. as ONSOLIS, and the Canadian tradename is to be determined.

3 Oct 2009

Auxilium Pharmaceuticals raises $115.7 million for general corporate purposes

Auxilium Pharmaceuticals, Inc. announced today that it has closed its previously announced public offering of 3,000,000 shares of its common stock at a price of $34.50 per share.

3 Oct 2009

Alexza enters into agreement with institutional investors to raise $19.7 million

Alexza Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement with various institutional investors to raise $19.7 million in a private placement of its common stock.

1 Oct 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

FDA grants priority review for Cephalon's sNDA

Cephalon, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year.

25 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.

17 Sep 2009

Preliminary results of Phase 2b clinical trial of AZ-104 announced by Alexza Pharmaceuticals

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced preliminary results from its 366 patient Phase 2b clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache.

14 Sep 2009

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

11 Sep 2009

Biodelivery Sciences International to participate in investor conferences

BioDelivery Sciences International, Inc. today announced its participation in the upcoming investor conferences.

3 Sep 2009

Corporate restructuring announced by Akela Pharma to achieve several operational objectives

Akela Pharma, Inc., (TSX: AKL) and its wholly owned manufacturing subsidiary, PharmaForm, today announced a comprehensive corporate restructuring designed to achieve several operational objectives.

3 Sep 2009

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

BioDelivery Sciences International to integrate its Newark operations with company’s headquarters in Raleigh

BioDelivery Sciences International, Inc. (Nasdaq: BDSI), today announced the consolidation of the company’s laboratory and other operations in Newark, New Jersey to the company’s headquarters in Raleigh, North Carolina. BDSI will vacate its Newark facility by September 30, 2009.

2 Sep 2009

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

27 Aug 2009

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today presented its consolidated half-year accounts to June 30, 2009.

27 Aug 2009

Fentanyl News and Research

Further Reading

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

Sosei R&D enters agreement with Pharmasol R&D to assign its rights to the assets of AD 923

FDA accepts ProStrakan's Abstral NDA filing for review

YM BioSciences to acquire Cytopia

BioDelivery Sciences International files NDS for BEMA Fentanyl

Auxilium Pharmaceuticals raises $115.7 million for general corporate purposes

Alexza enters into agreement with institutional investors to raise $19.7 million

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

FDA grants priority review for Cephalon's sNDA

Nimotuzumab drug approved for Mexican distribution

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Preliminary results of Phase 2b clinical trial of AZ-104 announced by Alexza Pharmaceuticals

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

Biodelivery Sciences International to participate in investor conferences

Corporate restructuring announced by Akela Pharma to achieve several operational objectives

CORD I phase III clinical trial results of XIAFLEX published

BioDelivery Sciences International to integrate its Newark operations with company’s headquarters in Raleigh

Alexza completes acquisition of Symphony Allegro after sharholders' approval

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News